Anpario
Website:
Anpario
Index:
AIM
EPIC: ANP
Supersector:
Health Care
Sector:
Pharmaceuticals and Biotechnology
Subsector:
Biotechnology
Market Cap:
£107.22M
Payout Frequency: Semi-Annual
Anpario Dividend Analysis and Summary
Key Dividend Details
- Declared dividend: Final dividend of 8.90p per share (FY24: 8.00p), taking the total FY2025 dividend to 12.50p (FY24: 11.25p), an +11% YoY increase.
- Ex-dividend date: 09/07/2026
- Record date: 10/07/2026
- Payment date: 24/07/2026
- Coverage: FY2025 basic EPS 40.20p implies dividend cover of ~3.2x (payout ratio ~31%).
- Cash cost: Company guidance indicates c. £1.62m for the final dividend; total FY2025 dividend c. £2.27m.
- Indicative yield: Using the 31 Dec 2025 share price of 475p, the FY2025 total dividend implies a trailing yield of ~2.6% (12.5p/475p).
- Status: Final dividend is subject to AGM approval (AGM scheduled 18/06/2026).
Dividend Sustainability and Growth
- Growth trajectory: The Board continues a progressive policy, raising both interim (3.60p vs 3.25p) and final (8.90p vs 8.00p), for an 11% total increase in FY2025.
- Earnings support: Strong operational year — revenue +24% to £47.2m, gross margin up to 50.9%, PBT +54% to £8.0m; EPS 40.20p comfortably covers the 12.50p dividend (c.3.2x cover).
- Cash flow and balance sheet: Operating cash flow £5.9m vs cash dividends paid £2.06m (c.35% of op cash); year-end cash £12.4m, no debt. This provides headroom to fund the dividend and modest investment.
- Capital intensity: Modest capex (£0.6m) with disciplined working capital; continued strong cash generation even after £1.0m Bio-Vet contingent consideration.
- FX risk management: Active USD hedging programme helps dampen earnings/cash flow volatility, indirectly supporting dividend stability.
Capital Allocation and Structural Factors
- M&A integration: Full-year contribution from Bio-Vet (acquired late 2024) with integration progressing well; combined Americas structure and cross-selling are enhancing growth and margins.
- Cash priorities: Management reiterates that cash is held to fund future acquisitions. While current cover is strong, an acceleration in M&A could, at the margin, compete with dividend growth for capital.
- Equity movements: Minor treasury share purchase (29,000 shares; ~£0.1m) and ongoing share-based schemes (JSOP/SAYE). Dilution limits targeted to trend to 15% by 2026; limited impact on per-share dividend cost.
- Route-to-market changes: Establishment of a subsidiary in Panama and distributor changes in Mexico/Central America should support medium-term revenue resilience.
Risks/Flags to Dividend Stability
- Geopolitical/logistics risk: Management is monitoring the conflict in Iran and regional shipping/logistics into parts of the Persian Gulf; potential for short-term disruption to demand or deliveries.
- Market concentration/competition: Ongoing competitive pressure in Brazil and broader feed additive markets; execution in weaker territories remains a watch-point.
- FX exposure: Material USD exposure managed via hedges; residual currency swings can still affect reported earnings and cash.
- Tax benefits sensitivity: Effective tax rate benefits from Patent Box; any adverse change could nudge payout capacity, though current cover provides a buffer.
- M&A execution risk: While Bio-Vet integration is progressing well, future acquisitions bring integration and return risks that could influence capital allocation priorities.
Read more
Anpario Annual Dividend Yield - 2.19%
Dividends Used in Calculation:
| Ex-Dividend Date |
Payment Date |
Type |
Amount |
Currency |
| 10/07/2025 |
25/07/2025 |
Final |
8.00p |
GBX |
| 13/11/2025 |
28/11/2025 |
Interim |
3.60p |
GBX |
Total (Annual Dividends Per Share):
11.60p
Dividend Yield =
Annual Dividends Per Share (11.60p)
÷ Share Price (530p)
= 2.19%
Anpario Dividend History
| Ex Dividend Date |
Payment Date |
Type |
Amount |
Currency |
| 09/07/2026 |
24/07/2026 |
Final |
8.9000p |
GBX |
| 13/11/2025 |
28/11/2025 |
Interim |
3.60p |
GBX |
| 10/07/2025 |
25/07/2025 |
Final |
8.00p |
GBX |
| 14/11/2024 |
29/11/2024 |
Interim |
3.25p |
GBX |
| 11/07/2024 |
26/07/2024 |
Final |
7.50p |
GBX |
| 09/11/2023 |
24/11/2023 |
Interim |
3.20p |
GBX |
| 13/07/2023 |
28/07/2023 |
Final |
7.35p |
GBX |
| 10/11/2022 |
25/11/2022 |
Interim |
3.15p |
GBX |
| 14/07/2022 |
29/07/2022 |
Final |
7.00p |
GBX |
| 11/11/2021 |
26/11/2021 |
Interim |
3.00p |
GBX |
| 15/07/2021 |
30/07/2021 |
Final |
6.25p |
GBX |
| 12/11/2020 |
27/11/2020 |
Interim |
2.75p |
GBX |
| 16/07/2020 |
31/07/2020 |
Final |
5.50p |
GBX |
| 14/11/2019 |
29/11/2019 |
Interim |
2.50p |
GBX |
| 11/07/2019 |
26/07/2019 |
Final |
5.00p |
GBX |
| 15/11/2018 |
30/11/2018 |
Interim |
2.20p |
GBX |
| 12/07/2018 |
27/07/2018 |
Final |
4.50p |
GBX |
| 16/11/2017 |
01/12/2017 |
Interim |
2.00p |
GBX |
| 13/07/2017 |
31/07/2017 |
Final |
5.50p |
GBX |
| 14/07/2016 |
29/07/2016 |
Final |
5.00p |
GBX |
| 16/07/2015 |
31/07/2015 |
Final |
4.50p |
GBX |
| 09/07/2014 |
25/07/2014 |
Final |
3.50p |
GBX |
| Year |
Interim |
Final |
Currency |
Total |
Change |
| 2024 |
3.250 |
7.500 |
GBX |
10.750 |
1.890 |
| 2023 |
3.200 |
7.350 |
GBX |
10.550 |
3.940 |
| 2022 |
3.150 |
7.000 |
GBX |
10.150 |
9.720 |
| 2021 |
3.000 |
6.250 |
GBX |
9.250 |
12.120 |
| 2020 |
2.750 |
5.500 |
GBX |
8.250 |
10.000 |
| 2019 |
2.500 |
5.000 |
GBX |
7.500 |
11.940 |
| 2018 |
2.200 |
4.500 |
GBX |
6.700 |
-10.660 |
| 2017 |
2.000 |
5.500 |
GBX |
7.500 |
50.000 |
| 2016 |
|
5.000 |
GBX |
5.000 |
11.110 |
| 2015 |
|
4.500 |
GBX |
4.500 |
28.570 |
| 2014 |
|
3.500 |
GBX |
3.500 |
|
Anpario Dividend Calculator
Anpario Dividend Growth
| Dividend Growth (1Y) |
11.11%
|
| Dividend CAGR (5Y) |
6.79%
|
| Years of Growth |
7
|
| Payout Ratio |
30.45%
|
| Buyback Yield |
-5.69%
|
| Shareholder Yield |
-3.34%
|
| P/E Ratio (TTM) | 13.97 |
| Forward P/E | 12.64 |
| P/FCF | 20.09 |
| Earnings Yield | 6.3% |
| FCF Yield | 4.98% |
| ROE | 17.48% |
| ROCE | 18.09% |
| Profit Margin | 14.31% |
| Operating Margin | 16.69% |
| Gross Margin | 50.93% |